Both have excellent safety profiles with no known interactions
Reported benefits (per available research): Studied for its ability to raise GH and IGF-1 toward youthful levels and blunt age-related loss of fat-free mass, based on a 2-year randomized, placebo-controlled trial in 65 healthy older adults (Nass et al., 2008, Annals of Internal Medicine, PMID 18981485)
24 months for the MiniQuick
A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
This preparation is supplied in a sealed sterile vial designed for controlled laboratory environments